View abstract

Cet abstract a été assigné à session OB Free papers: Glaucoma
TitreIs Inhibition of VEGF165 Sufficient to inhibit Scar Formation after Trabeculectomy?
Abstract Nr.324
ButWe have previously shown that VEGF plays a role in scar formation after glaucoma surgery and that inhibition of all VEGF-isoforms by bevacizumab is able to reduce scar formation. This study was designed to elucidate the exact role of VEGF165 in scar formation. The effect of pegaptanib (Pfizer), which specifically blocks VEGF165, was investigated in vitro and in vivo.
MéthodesThe effect of pegaptanib on Tenon fibroblasts and HUVEC in vitro was determined using a WST-1 proliferation assay. The effect of the aptamer was also investigated in vivo in a rabbit model for glaucoma surgery by studying angiogenesis, inflammation and collagen deposition.
RésultatsA dose-dependent reduction of HUVEC proliferation was seen after pegaptanib administration in vitro (P<0.05 with a dose of at least 0,3 mg/ml). 2 mg/ml was necessary to inhibit the proliferation of Tenon fibroblasts. The aptamer also significantly reduced blood vessel density 3 days after surgery in a rabbit model of trabeculectomy (P=0.001). There were no significant differences in inflammation and collagen deposition in the treated eyes compared to control.
ConclusionWhereas HUVEC cells were inhibited by pegaptanib in a dose-dependent way, Tenon fibroblasts were only inhibited at the highest dose. A single administration of pegaptanib at the time of trabeculectomy reduced postoperative angiogenesis, but not inflammation or collagen deposition. Further studies using repeated pegaptanib injections are necessary to investigate whether the lack of effect of pegaptanib on scarring was due to a shorter working time of pegaptanib compared to bevacizumab, or due to the difference in their effect on the various VEGF isoforms.
Auteur 1
NomVAN BERGEN
InitialesT
InstitutKU Leuven
VilleLeuven
Auteur 2
NomVAN DE VEIRE
InitialesS
InstitutKU Leuven
VilleLeuven
Auteur 3
NomVANDEWALLE
InitialesE
InstitutKU Leuven
VilleLeuven
Auteur 4
NomMOONS
InitialesL
InstitutKU Leuven
VilleLeuven
Auteur 5
NomSTALMANS
InitialesI
InstitutKU Leuven
VilleLeuven
top ^